Evidence map›Paper›PMID 41867491›Full record

ArticleEJC paediatric oncology2025

From the bench of molecular understanding to the bedside of optimal therapy for

Sarah K Tasian, Judith M Boer, Monique L den Boer

Abstract read
In one paragraph

Article in EJC paediatric oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. DifferentialHemaSphere · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sarah K TasianPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0003-1327-1662
Judith M BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Monique L den BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Funding

Multispecific targeting incorporating cytokine receptor pathways in high risk pediatric acute leukemias to improve durability of adoptive cell therapy-induced remissionsU01CA232486 · NCI · UNIVERSITY OF COLORADO DENVER · PI FRY, TERRY J., TASIAN, SARAH KATHLEEN · 2018 to 2018
$4.0M
Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic LeukemiaR01CA293587 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI LOH, MIGNON LEE-CHEUN, TASIAN, SARAH KATHLEEN · 2025 to 2025
$3.5M
Towards rational design of combination therapeutic targetsU01CA243072 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI TAN, KAI, TASIAN, SARAH KATHLEEN · 2020 to 2024
$2.6M
NCI NIH HHS R01 CA293587NCI NIH HHS U01 CA232486NCI NIH HHS U01 CA243072
6 · The paper itself

Abstract

This review aims to discuss similarities and dissimilarities between

Indexed as

ABL-classAcute lymphoblastic leukemiaBCR::ABL1BCR::ABL1-likeChildrenClinical trialsGeneticsImmunotherapyPh+Ph-likeTargeted therapyTyrosine kinase inhibitor

Identifiers

PMID41867491
PMCPMC13003754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.